Life sciences companies and the risks posed by the mifepristone litigation

At the Intersection of Science and Law

English - May 19, 2023 15:54 - 33 minutes - 30.5 MB
Life Sciences Science Technology covid19 fda mrna pfizer dlapiper law lawfirms legal pandemic vaccine Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Trade secrets protection in the life sciences sector

In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward.

See omnystudio.com/listener for privacy information.